Latest filings (excl ownership)
20-F
2023 FY
Annual report (foreign)
16 Apr 24
6-K
Connect Biopharma Reports Full Year 2023 Financial Results and Provides Business Update
16 Apr 24
6-K
Current report (foreign)
12 Feb 24
6-K
Connect Biopharma Announces Positive Rademikibart Global Phase 2b Topline Results in Adult Patients with Moderate-to-Severe Persistent Asthma
12 Dec 23
6-K
Exclusive License and Collaboration Agreement
21 Nov 23
6-K
Current report (foreign)
1 Nov 23
6-K
Current report (foreign)
20 Oct 23
6-K
Connect Biopharma Reports First Half 2023 Financial Results and Provides Business Update
12 Sep 23
6-K
Current report (foreign)
12 Sep 23
UPLOAD
Letter from SEC
10 Aug 23
CORRESP
Correspondence with SEC
24 Jul 23
6-K
Current report (foreign)
14 Jul 23
UPLOAD
Letter from SEC
11 Jul 23
6-K
House Lease Contract
23 Jun 23
6-K
Current report (foreign)
5 Jun 23
6-K
Current report (foreign)
1 Jun 23
6-K
Connect Biopharma Reports Full Year 2022 Financial Results
11 Apr 23
20-F
2022 FY
Annual report (foreign)
11 Apr 23
6-K
Connect Biopharma CBP-201 Atopic Dermatitis Global Phase 2b Data Showed Rapid and Sustained Improvement Across all Body Regions
21 Mar 23
6-K
Connect Biopharma Reports CBP-201 Global Phase 2 Asthma Trial Achieves Full Enrollment
8 Feb 23
6-K
Current report (foreign)
2 Feb 23
6-K
Connect Biopharma Provides Business and Clinical Development Program Update
30 Dec 22
6-K
Current report (foreign)
2 Dec 22
6-K
Current report (foreign)
4 Oct 22
6-K
Connect Biopharma Reports First Half 2022 Financial Results
13 Sep 22
6-K
Current report (foreign)
30 Aug 22
6-K
Current report (foreign)
19 Aug 22
6-K
Current report (foreign)
11 Jul 22
EFFECT
Notice of effectiveness
7 Jul 22
S-8
Registration of securities for employees
1 Jul 22
CORRESP
Correspondence with SEC
1 Jul 22
F-3/A
Shelf registration (foreign) (amended)
17 Jun 22
6-K
Current report (foreign)
17 Jun 22
CORRESP
Correspondence with SEC
17 Jun 22
6-K
Current report (foreign)
10 Jun 22
UPLOAD
Letter from SEC
3 Jun 22
F-3/A
Shelf registration (foreign) (amended)
20 May 22
CORRESP
Correspondence with SEC
20 May 22
6-K
Current report (foreign)
9 May 22
6-K
Current report (foreign)
5 May 22
Latest ownership filings
SC 13D/A
Panacea Innovation Ltd
27 Feb 24
SC 13D/A
RA CAPITAL MANAGEMENT, L.P.
27 Feb 24
SC 13D
Panacea Innovation Ltd
13 Feb 24
SC 13G/A
BioFortune Inc
13 Feb 24
SC 13G/A
Wei Zheng
13 Feb 24
SC 13D/A
RA CAPITAL MANAGEMENT, L.P.
20 Dec 23
144
Notice of proposed sale of securities
18 Dec 23
144
Notice of proposed sale of securities
18 Dec 23
SC 13D/A
RA CAPITAL MANAGEMENT, L.P.
14 Dec 23
144
Notice of proposed sale of securities
12 Dec 23
144
Notice of proposed sale of securities
12 Dec 23
SC 13D/A
RA CAPITAL MANAGEMENT, L.P.
4 Dec 23
144
Notice of proposed sale of securities
27 Nov 23
144
Notice of proposed sale of securities
27 Nov 23
144
Notice of proposed sale of securities
21 Nov 23
144
Notice of proposed sale of securities
21 Nov 23
SC 13G/A
Huang James
4 Oct 23
SC 13G/A
Qiming Venture Partners V, L.P.
14 Feb 23
SC 13G
Shanghai Minhui Enterprise Management Consulting Partnership (Limited Partnership)
13 Feb 23
SC 13G/A
Wei Zheng
13 Feb 23
SC 13G/A
BioFortune Inc
13 Feb 23
SC 13G/A
FMR LLC
9 Feb 23
SC 13G
Huang James
3 Jan 23
SC 13G
Wei Zheng
25 Feb 22
SC 13G
BioFortune Inc
25 Feb 22
SC 13G
Advantech Capital II L.P.
15 Feb 22
SC 13G
Qiming Venture Partners VII, L.P.
14 Feb 22
SC 13G
FMR LLC
9 Feb 22
SC 13D/A
RA CAPITAL MANAGEMENT, L.P.
7 Jun 21
SC 13D
RA CAPITAL MANAGEMENT, L.P.
29 Mar 21